Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described.

Matéria original

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

No significant benefit of moderate-dose vitamin C on severe COVID-19 cases